New York State Common Retirement Fund Has $281.24 Million Position in Pfizer Inc. (NYSE:PFE)

New York State Common Retirement Fund cut its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 9,768,604 shares of the biopharmaceutical company’s stock after selling 269,555 shares during the quarter. New York State Common Retirement Fund owned approximately 0.17% of Pfizer worth $281,238,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Adage Capital Partners GP L.L.C. lifted its stake in shares of Pfizer by 40.5% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock valued at $157,215,000 after purchasing an additional 1,365,295 shares during the period. LifePlan Financial LLC acquired a new position in shares of Pfizer in the 4th quarter valued at about $255,000. Brookstone Capital Management increased its position in Pfizer by 88.5% in the 3rd quarter. Brookstone Capital Management now owns 452,352 shares of the biopharmaceutical company’s stock valued at $14,109,000 after buying an additional 212,369 shares in the last quarter. ETF Store Inc. increased its position in Pfizer by 12.0% in the 3rd quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company’s stock valued at $214,000 after buying an additional 727 shares in the last quarter. Finally, KLCM Advisors Inc. increased its position in Pfizer by 75.0% in the 4th quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock valued at $5,004,000 after buying an additional 74,487 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Monday, April 15th. TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a research report on Thursday, January 4th. Guggenheim assumed coverage on Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price for the company. Finally, Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Eleven investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and a consensus price target of $36.33.

Pfizer Stock Performance

Shares of PFE stock traded up $0.26 during trading on Monday, hitting $26.26. The company’s stock had a trading volume of 35,667,868 shares, compared to its average volume of 42,342,027. The company has a market cap of $148.70 billion, a PE ratio of 72.94, a P/E/G ratio of 1.17 and a beta of 0.61. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The business has a fifty day moving average of $27.11 and a 200-day moving average of $28.62. Pfizer Inc. has a 52 week low of $25.23 and a 52 week high of $40.37.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. During the same period in the prior year, the company posted $1.14 earnings per share. Pfizer’s quarterly revenue was down 41.3% on a year-over-year basis. As a group, research analysts anticipate that Pfizer Inc. will post 2.24 earnings per share for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.